The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance
Abstract
Background —Hypercholesterolemia is causally associated with defects of endothelial nitric oxide (NO)–dependent vasodilation. Increased uptake of cholesterol by endothelial cells (ECs) upregulates the abundance of the structural protein caveolin-1 and impairs NO release through the stabilization of the inhibitory heterocomplex between caveolin-1 and endothelial NO synthase (eNOS). Therefore, we examined whether the hydroxy-methylglutaryl–coenzyme A reductase inhibitor atorvastatin modulates caveolin abundance, eNOS activity, and NO release through a reduction in endogenous cholesterol levels. Methods and Results —ECs were incubated with increasing doses of atorvastatin in the absence or in the presence of human LDL cholesterol (LDL-Chol) fractions in the presence of antioxidants. Our results show that atorvastatin (10 nmol/L to 1 μmol/L) reduced caveolin-1 abundance in the absence (−75%) and in the presence (−20% to 70%) of LDL-Chol. This was paralleled by a decreased inhibitory interaction between caveolin-1 and eNOS and a restoration and/or potentiation of the basal (+45%) and agonist-stimulated (+107%) eNOS activity. These effects were observed in the absence of changes in eNOS abundance and were reversed with mevalonate. In the presence of LDL-Chol, atorvastatin also promoted the agonist-induced association of eNOS and the chaperone Hsp90, resulting in the potentiation of eNOS activation. Conclusions —We provide biochemical and functional evidence that atorvastatin promotes NO production by decreasing caveolin-1 expression in ECs, regardless of the level of extracellular LDL-Chol. These findings highlight the therapeutic potential of inhibiting cholesterol synthesis in peripheral cells to correct NO-dependent endothelial dysfunction associated with hypercholesterolemia and possibly other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors
Laufs, U., La Fata, V., Plutzky, J., & Liao, J. K. (1998) · Circulation · doi:10.1161/01.cir.97.12.1129 · Cited by 1,839
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Dynamic activation of endothelial nitric oxide synthase by Hsp90
García-Cardeña, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A., & Sessa, W. C. (1998) · Nature · doi:10.1038/33934 · Cited by 1,029
Caveolins, Liquid-Ordered Domains, and Signal Transduction
Smart, E. J., Graf, G. A., McNiven, M. A., Sessa, W. C., Engelman, J. A., Scherer, P. E., Okamoto, T., & Lisanti, M. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7289 · Cited by 1,006
Simvastatin, an HMG–Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month
O'Driscoll, G., Green, D., & Taylor, R. R. (1997) · Circulation · doi:10.1161/01.cir.95.5.1126 · Cited by 952
Hernández-Perera, O., Pérez-Sala, D., Navarro-Antolín, J., Sánchez-Pascuala, R., Hernández, G., Díaz, C., & Lamas, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1500 · Cited by 763
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
Feron, O., Dessy, C., Moniotte, S., Desager, J.-P., & Balligand, J.-L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4829 · Cited by 413
Self-citationGuijarro, C., Blanco-Colio, L. M., Ortego, M., Alonso, C., Ortiz, A., Plaza, J. J., Díaz, C., Hernández, G., & Egido, J. (1998) · Circulation Research · doi:10.1161/01.res.83.5.490 · Cited by 390
Cited by
Nitric oxide synthases: regulation and function
Forstermann, U., & Sessa, W. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr304 · Cited by 4,409
Role of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513
Beneficial Cardiovascular Pleiotropic Effects of Statins
Davignon, J. (2004) · Circulation · doi:10.1161/01.cir.0000131517.20177.5a · Cited by 955
Homma, S., Sacco, R. L., Di Tullio, M. R., Sciacca, R. R., & Mohr, J. P. (2002) · Circulation · doi:10.1161/01.cir.0000017498.88393.44 · Cited by 949
Strategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 567
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
Behrendt, D., & Ganz, P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02963-6 · Cited by 499
Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis
Kawashima, S., & Yokoyama, M. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000125114.88079.96 · Cited by 453
Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice
Zhao, Y.-Y., Liu, Y., Stan, R.-V., Fan, L., Gu, Y., Dalton, N., Chu, P.-H., Peterson, K., Ross, J., & Chien, K. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172360799 · Cited by 448
S. Antonopoulos, A., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 432
Landmesser, U., Bahlmann, F., Mueller, M., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D., et al. (2005) · Circulation · doi:10.1161/01.cir.0000164260.82417.3f · Cited by 425
Landmesser, U., Engberding, N., Bahlmann, F. H., Schaefer, A., Wiencke, A., Heineke, A., Spiekermann, S., Hilfiker-Kleiner, D., Templin, C., Kotlarz, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143232.67642.7a · Cited by 423
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Endothelial function and coronary artery disease
Kinlay, S., Libby, P., & Ganz, P. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200108000-00003 · Cited by 384
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Fontana, J., Fulton, D., Chen, Y., Fairchild, T. A., McCabe, T. J., Fujita, N., Tsuruo, T., & Sessa, W. C. (2002) · Circulation Research · doi:10.1161/01.res.0000016837.26733.be · Cited by 344
Caveolae and Caveolins in the Cardiovascular System
Gratton, J.-P., Bernatchez, P., & Sessa, W. C. (2004) · Circulation Research · doi:10.1161/01.res.0000129178.56294.17 · Cited by 317
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1451 · Cited by 314
Kone, B. C., Kuncewicz, T., Zhang, W., & Yu, Z.-Y. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00048.2003 · Cited by 305
Förstermann, U., & Li, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01196.x · Cited by 300
Zafra, C., Abraldes, J. G., Turnes, J., Berzigotti, A., Fernández, M., Garcı́a-Pagán, J. C., Rodés, J., & Bosch, J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.007 · Cited by 297
R EGULATION OF N ITRIC O XIDE S YNTHESIS BY D IETARY F ACTORS
Wu, G., & Meininger, C. J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110901.145329 · Cited by 294
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 294
Hsp90 and Caveolin Are Key Targets for the Proangiogenic Nitric Oxide–Mediated Effects of Statins
Brouet, A., Sonveaux, P., Dessy, C., Moniotte, S., Balligand, J.-L., & Feron, O. (2001) · Circulation Research · doi:10.1161/hh2201.100319 · Cited by 269
Self-citationMyocardial infarction in young adults
Egred, M., Viswanathan, G., & Davis, G. K. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.027532 · Cited by 260
Mason, R. P., Walter, M. F., & Jacob, R. F. (2004) · Circulation · doi:10.1161/01.cir.0000129503.62747.03 · Cited by 175
Terasaka, N., Westerterp, M., Koetsveld, J., Fernández-Hernando, C., Yvan-Charvet, L., Wang, N., Sessa, W. C., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.213215 · Cited by 107
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Sun, H., & Singh, N. (2009) · Clinical Infectious Diseases · doi:10.1086/597039 · Cited by 65
Mechanisms underlying pleiotropic effects of statins.
Palaniswamy, C., Selvaraj, D. R., Selvaraj, T., & Sukhija, R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31819cdc86 · Cited by 35
Metadata
- Authors
- Feron, O., Dessy, C., Desager, J.-P., & Balligand, J.-L.
- Venue
- Circulation
- Published
- 2001-01-02
- Volume
- 103
- Issue
- 1
- Pages
- 113-118
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2162779892
- Cited by
- 417
- References
- 23
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.